2017 Archive
Blood's oxygen transporter revealed as power source for aggressive pediatric cancer
Read how the oncogene MYCN hijacks an oxygen-carrying component of hemoglobin to feed and grow aggressive AML in children.
ASH 2017: Preliminary results show gene therapy gains in SCID
Gene therapy for X-linked SCID resulted in the development of T cell, B cell and natural killer cells without side effects. Read more about the research.
ASH 2017: GATA3 in Ph-like acute lymphoblastic leukemia
Jun J. Yang, PhD, shares research presented at ASH that highlights the role the GATA3 oncogene plays in a high-risk subset of acute lymphoblastic leukemia.
ASH 2017: Learning, networking and recruiting at the annual hematology meeting
The annual American Society of Hematology (ASH) meeting offers St. Jude clinicians and researchers the opportunity to learn, network and recruit. Read more.
The St. Jude Equations: A better method of calculating kidney function
Learn about new equations to estimate kidney function in young cancer patients more quickly and accurately.
ASH 2017: Research on TP53 gene variations featured in first ALL session
Jun J. Yang, PhD, offers highlights of the first ALL session at the American Society of Hematology (ASH) meeting, including his work on TP53. Read more.
Math helps biologist calculate variance of blood progenitor cells
Find out how a researcher applied statistical analysis to chart variance and better understand how childhood leukemia develops.
Sickle cell study on path to improving therapies for children and adults
The Sickle Cell Clinical Research and Intervention Program uses data to determine therapies for children and adults. Learn more.
Trio’s award awakens effects of sleep and sleep patterns
Find out how poor sleep hampers treatment of young children with cancer
Brain studies provide treatment clues in unexpected fields
Research shows possible path to restoring critical regions of the brain involved with hearing loss by limiting a neuromodulator in the auditory thalamus.